APOB and atherosclerosis: Since 1959, when Gero et al. performed the first atheroprotective vaccination of rabbits with LDL [224], numerous studies in rodents have demonstrated that vaccination with either native, modified (oxidized) LDL, or (peptides from) ApoB has the potential to elicit a T-cellular immune response that prevents atherosclerosis [225,226,227,228,229,230,231,232,233,234].